Pages that link to "Q46113884"

The following pages link to The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). (Q46113884):

Displaying 40 items.

• Intravenous zoledronate for osteoporosis: less might be more (Q26738958) (← links)
• New insights into treatment of osteoporosis in postmenopausal women (Q26777910) (← links)
• Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research (Q26782621) (← links)
• Recent advances in the management of osteoporosis (Q33672136) (← links)
• Longitudinal Change in Trabecular Bone Score during and after Treatment of Osteoporosis in Postmenopausal Korean Women (Q33804839) (← links)
• Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy (Q37009387) (← links)
• Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study (Q37046213) (← links)
• New horizons in treatment of osteoporosis. (Q37630995) (← links)
• Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis (Q37661855) (← links)
• Short-term and long-term effects of osteoporosis therapies. (Q38473594) (← links)
• The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women (Q38611601) (← links)
• Bisphosphonate drug holidays--when, why and for how long? (Q38617760) (← links)
• Deprescribing: An Application to Medication Management in Older Adults (Q38855300) (← links)
• Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. (Q38918810) (← links)
• Review: Breaking From Bisphosphonates (Q38992765) (← links)
• Zoledronic Acid (Reclast®, Aclasta®): A Review in Osteoporosis (Q39013796) (← links)
• Using Osteoporosis Therapies in Combination (Q39408210) (← links)
• Use of bone turnover markers in postmenopausal osteoporosis. (Q39423898) (← links)
• The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: Which therapies work best? a network meta-analysis (Q41204558) (← links)
• For how long should osteoporosis treatment continue? (Q45779903) (← links)
• Bisphosphonate drug holidays: we reap what we sow. (Q46648831) (← links)
• Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday (Q48069145) (← links)
• Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. (Q48105410) (← links)
• Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study. (Q50623601) (← links)
• Comments on Kamimura et al.: significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients (Q51166639) (← links)
• Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report. (Q51532298) (← links)
• Minodronate for the treatment of osteoporosis. (Q55077666) (← links)
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women (Q57465255) (← links)
• Advances and Unmet Needs in the Therapeutics of Bone Fragility (Q58761409) (← links)
• Socioeconomic status and risk of osteoporotic fractures and the use of DXA scans: data from the Danish population-based ROSE study (Q64120869) (← links)
• Under-Recognition of Fractures as Osteoporosis Indicators (Q64232476) (← links)
• Lactobacillus helveticus (ATCC 27558) upregulates Runx2 and Bmp2 and modulates bone mineral density in ovariectomy-induced bone loss rats. (Q64994748) (← links)
• Denosumab after 8 years (Q86501823) (← links)
• Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice (Q90354923) (← links)
• A broader strategy for osteoporosis interventions (Q90591196) (← links)
• Drug holidays in osteoporosis treatment: mind the gaps! (Q90736737) (← links)
• Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment (Q91939368) (← links)
• Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates (Q92481670) (← links)
• Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group (Q92762387) (← links)
• Quantitative bone single photon emission computed tomography analysis of the effects of duration of bisphosphonate administration on the parietal bone (Q100634157) (← links)